Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},f=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var m=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===m&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NYSE - Nasdaq Real Time Price • USD

Compare

41.93 +0.89 (+2.17%)

At close: June 21 at 4:00 PM EDT

41.88 -0.05 (-0.12%)

After hours: June 21 at 7:59 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for BMY

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 41.04
Open 41.26
Bid 41.82 x 1100
Ask 41.98 x 1200
Day's Range 41.07 - 41.94
52 Week Range 39.63 - 65.38
Volume 34,787,660
Avg. Volume 14,291,974
Market Cap (intraday) 84.996B
Beta (5Y Monthly) 0.43
PE Ratio (TTM) --
EPS (TTM) -3.10
Earnings Date Jul 26, 2024
Forward Dividend & Yield 2.40 (5.72%)
Ex-Dividend Date Jul 5, 2024
1y Target Est 52.25

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

www.bms.com

34,100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - General

Industry

More about Bristol-Myers Squibb Company

Recent News: BMY

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

BMYBristol-Myers Squibb Company

41.93

+2.17%

Mkt Cap 84.996B